Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

82.74 -0.75 (-0.90%)
Streaming Delayed Price Updated: 11:59 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
We're starting off Thursday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning. 
Via InvestorPlace
News headline image
Analyst Boosts Protagonist Therapeutics Price Target, Says Psoriasis Data Impressive ↗
JMP Securities has increased the price target for Protagonist Therapeutics Inc (NASDAQ: PTGX) from $28 to $35,  
Via Benzinga
News headline image
Expert Ratings for Protagonist Therapeutics ↗
 
Via Benzinga
News headline image
Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday ↗
Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at... 
Via Benzinga
News headline image
Where Protagonist Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Chart Of The Day: Protagonist Therapeutics - Wide Opinions ↗
Via Talk Markets
News headline image
Protagonist Therapeutics: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
4 Analysts Have This to Say About Protagonist Therapeutics ↗
 
Via Benzinga
News headline image
Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment ↗
Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2b FRONTIER 1 trial of the oral interleukin-23 receptor (IL-23R) antagonist JNJ-2113 (formerly PN-235) in adult... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Li Auto Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers PolyMet Mining Corp. (NYSE: PLM) shares surged 144% to $1.92 after the company announced Glencore made a non-binding proposal to acquire the company for $2.11 per share. 
Via Benzinga
News headline image
Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study ↗
 
Via Benzinga
News headline image
AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares... 
Via Benzinga
News headline image
US Stocks Mixed; Dow Falls Over 50 Points ↗
U.S. stocks traded mixed this morning, with the Dow Jones dropping more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.19% to 34,341.91 while the NASDAQ rose 0.28%... 
Via Benzinga
News headline image
Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment ↗
Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of  
Via Benzinga
News headline image
Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm ↗
The company is targeting psoriasis with a first-ever mechanism that could rival leaders. 
Via Investor's Business Daily
News headline image
Why Shares of Protagonist Therapeutics Rose This Week ↗
The company's lead pipeline candidate is making news. 
Via The Motley Fool
News headline image
Why Protagonist Therapeutics Shares Are Trading Higher Today ↗
 
Via Benzinga
News headline image
Why Protagonist Therapeutics Shares Are Nosediving ↗
Protagonist Therapeutics Inc (NASDAQ: PTGX) shares are trading lower by 9.68% to $19.46 Wednesday morning after the company announced pricing of a $100 million public offering of shares of common... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones dropping around 150 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the... 
Via Benzinga
News headline image
Top 5 Health Care Stocks That May Collapse In February ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Protagonist Therapeutics Earnings Perspective: Return On Capital Employed ↗
Protagonist Therapeutics (NASDAQ:PTGX) brought in sales totaling $859 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 96.07%, resulting in a loss of $41.04... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million. 
Via Benzinga
News headline image
3 Biotech Stocks to Buy Before They Boom ↗
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.